NDC-11 (Package) | NDC-9 (Product) (Ascending) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00078-0682-66 | 00078-0682 | Dabrafenib | Tafinlar | 50.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | April 12, 2016 | In Use | |
00078-0683-06 | 00078-0683 | Nelarabine | Arranon | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Oct. 5, 2016 | In Use | |
00078-0683-61 | 00078-0683 | Nelarabine | Arranon | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Aug. 2, 2019 | In Use | |
00078-0690-61 | 00078-0690 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Feb. 1, 2016 | In Use | |
00078-0694-48 | 00078-0694 | ceritinib | ZYKADIA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Oral | March 18, 2019 | In Use | |
00078-0694-84 | 00078-0694 | ceritinib | ZYKADIA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Oral | March 18, 2019 | In Use | |
00078-0698-02 | 00078-0698 | RYDAPT | Rydapt | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | April 28, 2017 | In Use | |
00078-0698-19 | 00078-0698 | RYDAPT | Rydapt | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | April 28, 2017 | In Use | |
00078-0698-51 | 00078-0698 | RYDAPT | Rydapt | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | April 28, 2017 | In Use | |
00078-0698-99 | 00078-0698 | RYDAPT | Rydapt | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | April 28, 2017 | In Use |
Found 10,000 results in 2 milliseconds — Export these results